• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Incidence of CMV-HCV coinfection in renal transplant recipient.肾移植受者中巨细胞病毒(CMV)与丙型肝炎病毒(HCV)合并感染的发生率。
BMJ Case Rep. 2012 Apr 2;2012:bcr1220115314. doi: 10.1136/bcr.12.2011.5314.
2
Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.伐昔洛韦预防与抢先治疗在巨细胞病毒阳性肾移植受者中的应用:一项随机临床试验的 1 年结果。
Transplantation. 2012 Jan 15;93(1):61-8. doi: 10.1097/TP.0b013e318238dab3.
3
Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?盐酸缬更昔洛韦(万赛维)对肝移植受者的巨细胞病毒感染有有效的预防作用吗?
Transplant Proc. 2005 Sep;37(7):3182-6. doi: 10.1016/j.transproceed.2005.07.032.
4
Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-organ failure with fatal outcome: a case report.一名接受肾移植的患者再次发生严重巨细胞病毒感染,接受更昔洛韦、来氟米特和免疫球蛋白治疗,出现包括癫痫发作、急性丙型肝炎病毒感染、药物性全血细胞减少、糖尿病、胆管炎以及多器官功能衰竭并导致死亡等并发症:病例报告
Ann Transplant. 2015 Mar 27;20:169-74. doi: 10.12659/AOT.892076.
5
Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.口服缬更昔洛韦预防心脏移植患者巨细胞病毒感染的效果
Drug Des Devel Ther. 2012;6:289-95. doi: 10.2147/DDDT.S36578. Epub 2012 Oct 12.
6
Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.低剂量缬更昔洛韦预防肾移植受者巨细胞病毒病的疗效和安全性:一项单中心回顾性分析
Pharmacotherapy. 2004 Oct;24(10):1323-30. doi: 10.1592/phco.24.14.1323.43152.
7
Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.来氟米特作为一名血清阴性肾移植受者耐更昔洛韦巨细胞病毒感染的挽救治疗——病例报告
Ann Transplant. 2014 Jan 30;19:60-3. doi: 10.12659/AOT.884035.
8
Gastric ulcer and duodenitis associated with coinfection of human herpesvirus-8 and cytomegalovirus in a renal transplant recipient: a case report.肾移植受者中人类疱疹病毒 8 型和巨细胞病毒合并感染与胃溃疡和十二指肠炎相关:一例报告。
BMC Nephrol. 2023 Mar 24;24(1):69. doi: 10.1186/s12882-023-03127-z.
9
Human cytomegalovirus and kidney transplantation: a clinician's update.人巨细胞病毒与肾移植:临床医生的最新知识更新。
Am J Kidney Dis. 2011 Jul;58(1):118-26. doi: 10.1053/j.ajkd.2011.04.010.
10
Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.肾移植和肾胰联合移植后抢先治疗中,口服缬更昔洛韦和静脉注射更昔洛韦对巨细胞病毒DNA载量的降低作用相似。
Antivir Ther. 2005;10(1):119-23.

引用本文的文献

1
A Decade-Long Cohort Analysis of Human Cytomegalovirus (HCMV)-Induced Early and Late Renal Rejection in Post-Transplant Patients in the Eastern Indian Population.一项针对东印度人群移植后患者中人类巨细胞病毒(HCMV)诱导的早期和晚期肾排斥的长达十年的队列分析。
Viruses. 2024 May 25;16(6):847. doi: 10.3390/v16060847.
2
Concomitant Polyoma BK Virus and West Nile Virus in Renal Allografts.肾移植受者中BK多瘤病毒与西尼罗河病毒共感染
Pathogens. 2023 Dec 15;12(12):1456. doi: 10.3390/pathogens12121456.

本文引用的文献

1
Viral infection in the renal transplant recipient.肾移植受者中的病毒感染。
J Am Soc Nephrol. 2005 Jun;16(6):1758-74. doi: 10.1681/ASN.2004121113. Epub 2005 Apr 13.
2
Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation.丙型肝炎感染、肾脏替代治疗时间与肾移植后的结局
Transplantation. 2004 Sep 15;78(5):745-50. doi: 10.1097/01.tp.0000131948.29742.24.
3
Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico.墨西哥城一家三级护理医院血液透析患者中丙型肝炎病毒感染的患病率。
J Clin Microbiol. 2004 Sep;42(9):4321-2. doi: 10.1128/JCM.42.9.4321-4322.2004.
4
Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients.
Transplantation. 2004 Jun 27;77(12):1894-6. doi: 10.1097/01.tp.0000131151.07818.d7.
5
Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients.荟萃分析:干扰素用于治疗透析患者的慢性丙型肝炎
Aliment Pharmacol Ther. 2003 Dec;18(11-12):1071-81. doi: 10.1046/j.1365-2036.2003.01780.x.
6
Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin.肾移植后联合使用α-2b干扰素和利巴韦林成功治疗丙型肝炎
J Hepatol. 2003 Nov;39(5):875-8. doi: 10.1016/s0168-8278(03)00358-1.
7
Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.干扰素单药治疗慢性丙型肝炎透析患者:疗效与安全性的文献分析
Am J Gastroenterol. 2003 Jul;98(7):1610-5. doi: 10.1111/j.1572-0241.2003.07526.x.
8
Evidence of active cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases.从炎症性肠病患者获取的组织标本中存在活动性巨细胞病毒感染及白细胞介素-6产生增加的证据。
Inflamm Bowel Dis. 2003 May;9(3):154-61. doi: 10.1097/00054725-200305000-00002.
9
Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.
Am J Transplant. 2003 Jan;3(1):74-8. doi: 10.1034/j.1600-6143.2003.30113.x.
10
Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients.血液透析患者丙型肝炎病毒感染的患病率及危险因素:一项针对2796例患者的多中心研究
Gut. 2002 Sep;51(3):429-33. doi: 10.1136/gut.51.3.429.

肾移植受者中巨细胞病毒(CMV)与丙型肝炎病毒(HCV)合并感染的发生率。

Incidence of CMV-HCV coinfection in renal transplant recipient.

作者信息

Chakraborty Avirup, Patil Krishna, Dasgupta Sanjay, Tarafdar Abhijit, Chakrabarti Sekhar, Chakraborty Nilanjan

机构信息

Virology Department, ICMR Virus Unit, Kolkata, India.

出版信息

BMJ Case Rep. 2012 Apr 2;2012:bcr1220115314. doi: 10.1136/bcr.12.2011.5314.

DOI:10.1136/bcr.12.2011.5314
PMID:22602835
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3339168/
Abstract

The authors report a case of a 47-year-old cytomegalovirus (CMV) immunoglobulin G (IgG) seropositive male patient with end stage renal disease who received a live renal transplant from a CMV IgG seropositive donor. Six months post-transplantation, the patient presented with reduced renal allograft function associated with fever, severe breathlessness, new onset jaundice and pancytopenia. His CMV DNA PCR came positive. Hepatitis C virus (HCV) RNA PCR also came positive (genotype I) though anti-HCV test performed before and after transplantation was negative. The patient was treated with oral valganciclovir and showed improvement of his clinical condition and was subsequently discharged under supervised therapy. However, the patient could not be treated for HCV because of risk of renal allograft rejection. The authors suggest oral valganciclovir for management of CMV infection and proper detection and eradication of HCV before renal transplantation to avoid future complications and prolongation of allograft survival.

摘要

作者报告了一例47岁的巨细胞病毒(CMV)免疫球蛋白G(IgG)血清学阳性的男性终末期肾病患者,该患者接受了来自CMV IgG血清学阳性供体的活体肾移植。移植后6个月,患者出现移植肾功能减退,伴有发热、严重呼吸困难、新发黄疸和全血细胞减少。他的CMV DNA聚合酶链反应(PCR)呈阳性。丙型肝炎病毒(HCV)RNA PCR也呈阳性(I型基因型),尽管移植前后进行的抗HCV检测均为阴性。患者接受了口服缬更昔洛韦治疗,临床状况有所改善,随后在监督治疗下出院。然而,由于存在肾移植排斥风险,该患者无法接受HCV治疗。作者建议使用口服缬更昔洛韦治疗CMV感染,并在肾移植前对HCV进行适当检测和根除,以避免未来并发症并延长移植肾存活时间。